BiotechTube

S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focus: Assess Post Infusion Viability of S303 RBCs

Conditions

Focus: Assess Post Infusion Viability of S303 RBCs

Trial Timeline

Oct 1, 2012 → Nov 1, 2014

NCT ID
NCT01711346

About S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs)

S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) is a phase 2 stage product being developed by Cerus for Focus: Assess Post Infusion Viability of S303 RBCs. The current trial status is completed. This product is registered under clinical trial identifier NCT01711346. Target conditions include Focus: Assess Post Infusion Viability of S303 RBCs.

What happened to similar drugs?

0 of 1 similar drugs in Focus: Assess Post Infusion Viability of S303 RBCs were approved

Approved (0) Terminated (0) Active (1)
🔄S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlCerusPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01711346Phase 2Completed

Competing Products

2 competing products in Focus: Assess Post Infusion Viability of S303 RBCs

See all competitors
ProductCompanyStageHype Score
Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solutionSwedish Orphan BiovitrumPhase 1
29
S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - ControlCerusPhase 3
30